GMED Globus Medical (GMED) Insider Trading, Ownership & Congress Trades
Medical Devices · Surgical & medical instruments & apparatus · CIK 0001237831
Congress · 1Form 144 · 2
Insider buyers, 180 days
0
Funds added, last quarter
335
13F, latest reported quarter
Conversions, 180 days
5
Codes C/M, not in net · $4.4M priced
What the filings say about GMED
Insiders, 180 days
-$6.4M net sold
3 sellers · 0% of sales under a 10b5-1 plan
Congress, 1 year
1 bought · 0 sold
Latest: purchase, 2026-09-03
Planned sales (Form 144), 90 days
$4.4M
2 notices
Globus Medical insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, GLOBUS MEDICAL INC insiders sold a net $6.4M of stock across 54 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 3 earlier Form 4 trades (code P or S) here by this insider (3 sales), the last on Mar 15, 2022.
- 1 other insider sold within 30 days.
- 335 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director TOBIN JAMES R sold about $2.2M of GMED on Sep 15, 2026, the largest insider sale at the company since 2024; 1 other insider sold within 30 days and 335 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Nov 11, 2025.
- 1 other insider sold within 30 days.
- 335 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director ZARRILLI STEPHEN T sold about $2.2M of GMED on Aug 18, 2026, the largest insider sale at the company since 2024; 1 other insider sold within 30 days and 335 funds added in the latest 13F quarter.Context
- 10 earlier Form 4 trades (code P or S) here by this insider (10 sales), the last on Nov 12, 2025.
- The trade is 4.9% of the 510,175 shares held after it.
- No other insider sold within 30 days.
- 335 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Davidar David D sold about $2.0M of GMED on Jun 5, 2026; 335 funds added in the latest 13F quarter.Context
- 10 earlier Form 4 trades (code P or S) here by this insider (10 sales), the last on Feb 12, 2026.
- No other insider sold within 30 days.
- 335 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP, GC, Corporate Secretary Huller Kelly sold about $1.9M of GMED on Feb 25, 2026; 335 funds added in the latest 13F quarter.Context
- 9 earlier Form 4 trades (code P or S) here by this insider (9 sales), the last on Nov 25, 2025.
- No other insider sold within 30 days.
- 335 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP, GC, Corporate Secretary Huller Kelly sold about $876.7K of GMED on Feb 12, 2026; 335 funds added in the latest 13F quarter.54 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$6.4M over 180 days
-$4.4M over 90 days
below 82% of Medical Devices
Congress
1 member bought in the last year
the lowest in Medical Devices
Funds
335 funds bought in last quarter
more than 90% of Medical Devices
Revenue
+16.7% year over year
more than 66% of Medical Devices
Margin
18.3% net margin
more than 91% of Medical Devices
Buybacks
$136.1M repurchased, FY to 2026-06-30
more than 68% of Medical Devices
Short interest
7.4% of the float short (float per yahoo 2026-10-27) · 5.5 days to cover · settled 2026-10-15
more than 72% of Medical Devices
What changed in the last 30 days
Oct 12Rep. Gilbert Cisneros sold $1.0K to $15K, disclosed 39 days after the trade
Why it matters
House members report a bracket, not an exact amount, and have 45 days to do it; the trade is weeks old when it becomes public.
Watch GMED
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+30.3%12M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns GMED: institutional holders (13F)
13F holdings, latest reported quarter
10,806,724 sh
$853.8M
8,200,423 sh
$647.9M
5,107,532 sh
$403.5M
4,994,385 sh
$394.6M
4,309,771 sh
$340.5M
Congress trades in GMED
STOCK Act disclosures, US House only, filed up to 45 days after the trade
Bought 2026-09-03 · disclosed 39 days later
$1,001 - $15,000
Bought 2026-08-19 · disclosed 22 days later
$15,001 - $50,000
Bought 2026-03-03 · disclosed 35 days later
$1,001 - $15,000
Sold 2025-07-10 · disclosed 34 days later
$1,001 - $15,000
Sold 2025-06-24 · disclosed 50 days later
$1,001 - $15,000
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
GMED planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
TOBIN JAMES R
Filed 2026-09-15
$2.2M
ZARRILLI STEPHEN T
Filed 2026-08-18
$2.2M
GMED mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Paradigm Select Fund
$10.9M position · as of 2026-06-30
3.9%
GMO Small Cap Quality Fund
$24.9M position · as of 2026-05-31
3.5%
Geneva SMID Cap Growth Fund
$1.4M position · as of 2026-05-31
3.2%
Nationwide Geneva Small Cap Growth Fund
$28.0M position · as of 2026-07-31
3.2%
AlphaCentric Robotics and Automation Fund
$790.1K position · as of 2026-06-30
3.0%
Virtus KAR Mid-Cap Core Fund
$51.2M position · as of 2026-06-30
2.9%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $6.4M sold by insiders over 180 days, 335 funds added last quarter, 1 House member(s) bought in 12 months, disclosed weeks after the trade, $4.4M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
GMED financials
Revenue growth
+16.7%
XBRL, annual
Net margin
18.3%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$3.1B
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM GMED
| FY Dec 2025 | $2.9B |
| FY Dec 2024 | $2.5B |
| FY Dec 2023 | $1.6B |
| FY Dec 2022 | $1.0B |
| FY Dec 2021 | $958.1M |
| Jun 2026 | $789.6M |
| Mar 2026 | $759.9M |
| Dec 2025 | $826.4M |
| Sep 2025 | $769.0M |
| Jun 2025 | $745.3M |
| Mar 2025 | $598.1M |
| Dec 2024 | $657.3M |
| Sep 2024 | $625.7M |
At each fiscal year end
Single quarter
Net margin, TTM
+17.0%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM GMED
| FY Dec 2025 | +18.3% |
| FY Dec 2024 | +4.1% |
| FY Dec 2023 | +7.8% |
| FY Dec 2022 | +18.6% |
| FY Dec 2021 | +15.6% |
| Jun 2026 | +19.2% |
| Mar 2026 | +16.4% |
| Dec 2025 | +17.0% |
| Sep 2025 | +15.5% |
| Jun 2025 | +27.2% |
| Mar 2025 | +12.6% |
| Dec 2024 | +4.0% |
| Sep 2024 | +8.3% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$755.6M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM GMED
| FY Dec 2025 | $588.8M |
| FY Dec 2024 | $405.2M |
| FY Dec 2023 | $165.2M |
| FY Dec 2022 | $104.4M |
| FY Dec 2021 | $219.4M |
| Jun 2026 | $176.6M |
| Mar 2026 | $162.7M |
| Dec 2025 | $202.4M |
| Sep 2025 | $213.9M |
| Jun 2025 | $31.3M |
| Mar 2025 | $141.2M |
| Dec 2024 | $193.2M |
| Sep 2024 | $161.7M |
At each fiscal year end
Single quarter
Debt to equity
0.09x
long-term debt only, 2023-12-31 (30 months older than the period end); equity 2026-06-30
Debt to equity GMED
| FY Dec 2025 | 0.09x |
| FY Dec 2024 | 0.10x |
| FY Dec 2023 | 0.10x |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | 0.09x |
| Mar 2026 | 0.09x |
| Dec 2025 | 0.09x |
| Sep 2025 | 0.09x |
| Jun 2025 | 0.10x |
| Mar 2025 | 0.10x |
| Dec 2024 | 0.10x |
| Sep 2024 | 0.10x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
2.18x
TTM operating cash flow over long-term debt only, 2023-12-31 (30 months older than the period end)
Cash flow to debt GMED
| FY Dec 2025 | 1.81x |
| FY Dec 2024 | 1.25x |
| FY Dec 2023 | 0.58x |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | 2.18x |
| Mar 2026 | 1.87x |
| Dec 2025 | 1.81x |
| Sep 2025 | 1.71x |
| Jun 2025 | 1.60x |
| Mar 2025 | 1.55x |
| Dec 2024 | 1.25x |
| Sep 2024 | 0.99x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+11.8%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity GMED
| FY Dec 2025 | +12.3% |
| FY Dec 2024 | +2.5% |
| FY Dec 2023 | +4.2% |
| FY Dec 2022 | +10.6% |
| FY Dec 2021 | +9.2% |
| Jun 2026 | +11.8% |
| Mar 2026 | +13.3% |
| Dec 2025 | +12.3% |
| Sep 2025 | +10.0% |
| Jun 2025 | +8.6% |
| Mar 2025 | +4.6% |
| Dec 2024 | +2.5% |
| Sep 2024 | +2.2% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+10.2%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets GMED
| FY Dec 2025 | +10.2% |
| FY Dec 2024 | +2.0% |
| FY Dec 2023 | +3.4% |
| FY Dec 2022 | +9.4% |
| FY Dec 2021 | +8.2% |
| Jun 2026 | +10.2% |
| Mar 2026 | +11.6% |
| Dec 2025 | +10.2% |
| Sep 2025 | +8.3% |
| Jun 2025 | +7.2% |
| Mar 2025 | +3.8% |
| Dec 2024 | +2.0% |
| Sep 2024 | +1.8% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
+11.7%
operating income after a 18.9% effective tax rate, over long-term debt only, 2023-12-31 (30 months older than the period end) plus average of 2025-06-30 and 2026-06-30 minus cash
Return on invested capital GMED
| FY Dec 2025 | +10.3% |
| FY Dec 2024 | +3.8% |
| FY Dec 2023 | +3.2% |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | +11.7% |
| Mar 2026 | +11.1% |
| Dec 2025 | +10.3% |
| Sep 2025 | +8.8% |
| Jun 2025 | +7.1% |
| Mar 2025 | +5.6% |
| Dec 2024 | +3.8% |
| Sep 2024 | +2.0% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
+13.4%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed GMED
| FY Dec 2025 | +10.4% |
| FY Dec 2024 | +3.7% |
| FY Dec 2023 | +4.0% |
| FY Dec 2022 | +12.2% |
| FY Dec 2021 | +10.2% |
| Jun 2026 | +13.4% |
| Mar 2026 | +11.5% |
| Dec 2025 | +10.4% |
| Sep 2025 | +8.3% |
| Jun 2025 | +6.4% |
| Mar 2025 | +6.0% |
| Dec 2024 | +3.7% |
| Sep 2024 | +2.5% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
20.98x
close 2026-10-26 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
P/E, trailing GMED
| FY Dec 2025 | 22.22x |
| FY Dec 2024 | 110.28x |
| FY Dec 2023 | 46.34x |
| FY Dec 2022 | 39.93x |
| FY Dec 2021 | 50.49x |
| Jun 2026 | 20.26x |
| Mar 2026 | 20.08x |
| Dec 2025 | 22.22x |
| Sep 2025 | 18.47x |
| Jun 2025 | 22.70x |
| Mar 2025 | 54.63x |
| Dec 2024 | 110.28x |
| Sep 2024 | 110.06x |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$10.9B
market value at close 2026-10-26 on 2026-08-04 shares, plus long-term debt only, 2023-12-31 (30 months older than the period end), minus cash 2026-06-30
Enterprise value GMED
| FY Dec 2025 | $11.6B |
| FY Dec 2024 | $10.9B |
| FY Dec 2023 | $7.5B |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | $10.6B |
| Mar 2026 | $11.5B |
| Dec 2025 | $11.6B |
| Sep 2025 | $7.4B |
| Jun 2025 | $7.6B |
| Mar 2025 | $9.7B |
| Dec 2024 | $10.9B |
| Sep 2024 | $9.9B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+6.9%
TTM free cash flow over market value at close 2026-10-26
FCF yield GMED
| FY Dec 2025 | +5.0% |
| FY Dec 2024 | +3.6% |
| FY Dec 2023 | +2.3% |
| FY Dec 2022 | +1.4% |
| FY Dec 2021 | +3.0% |
| Jun 2026 | +7.0% |
| Mar 2026 | +5.2% |
| Dec 2025 | +5.0% |
| Sep 2025 | +7.5% |
| Jun 2025 | +6.6% |
| Mar 2025 | +5.2% |
| Dec 2024 | +3.6% |
| Sep 2024 | +3.0% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
0.42x
P/E over trailing EPS growth of 50%: four quarters to 2026-06-30 against the four to 2025-06-30
PEG, trailing GMED
| FY Dec 2025 | 0.05x |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | 1.33x |
| FY Dec 2021 | 1.17x |
| Jun 2026 | 0.41x |
| Mar 2026 | 0.09x |
| Dec 2025 | 0.05x |
| Sep 2025 | 0.05x |
| Jun 2025 | 0.03x |
| Mar 2025 | 0.47x |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $2.9B | $2.5B | $1.6B | $1.0B |
| Gross profit | n/a | n/a | $1.0B | $759.1M |
| Operating income | $479.8M | $166.0M | $133.1M | $228.0M |
| Net income | $537.9M | $103.0M | $122.9M | $190.2M |
| EPS (diluted) | 3.92 | 0.75 | 1.07 | 1.85 |
| Operating cash flow | $753.4M | $520.6M | $243.5M | $178.5M |
| Cash | $526.2M | $784.4M | n/a | n/a |
| Long-term debt | n/a | n/a | $417.4M | n/a |
| Buybacks | $300.5M | $85.8M | $225.6M | $144.5M |
SEC XBRL, fiscal years, as known on 2026-10-28
GMED Stock Sonar score 6/7 axes
Find similar shapesCompareGMED ranks highest on financial health (81st percentile) and institutional and government (81st), and lowest on insider conviction (8th), among Medical Devices peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
GMED filings, in plain words
Are Globus Medical insiders buying or selling GMED?
In the 180 days to 2026-10-28, Globus Medical insiders were net sellers, a net $6.4M across purchases and sales reported on Form 4, by 3 sellers.
Have members of Congress traded GMED?
Yes. In the year to 2026-10-28, 1 House member disclosed buying GMED and 0 House members disclosed selling it; the latest on record is a purchase by Gilbert Cisneros dated 2026-09-03.
Are there planned insider sales of GMED?
Yes. 2 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $4.4M of stock; the latest, by TOBIN JAMES R, was filed 2026-09-15.
Read the full summary
In the 180 days to 2026-10-28, Globus Medical insiders were net sellers of GMED, a net $6.4M across purchases and sales reported on Form 4 by 3 sellers. None of the 3 insider sales was flagged as made under a Rule 10b5-1 plan. In the year to 2026-10-28, 1 member of Congress disclosed buying GMED and 0 members disclosed selling it; the latest on record is a purchase by Gilbert Cisneros dated 2026-09-03. Insiders filed 2 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $4.4M of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
